Explainable AI for Cancer Drug Response Prediction: Beyond Univariate Feature Attributions
Predicting cancer drug response from transcriptomic profiles is a cornerstone of precision oncology, yet the scientific value of machine learning models hinges not solely on predictive accuracy, but also on their capacity to generate reliable biological insights. Current explainability approaches in this setting are computationally costly, lack robustness, and reduce complex drug response to univariate gene importance scores, overlooking the coordinated gene activity that drives sensitivity and resistance. In this work, we present ILLUME+, a scalable post-hoc explainability framework that move
Lineage graph
Paper → model → repo connections mined from source citations (Tier-1 exact match).
Why these links exist
Every edge carries a method, confidence, and the source snippet that justified it — so bad links are debuggable.
- PossiblePossibly related (embedding) · 45%AI Is Accelerating Drug Discovery, but Patients Will Prove Its True Value - Technology Networks →
- PossiblePossibly related (embedding) · 50%rdk/p2rank →
- PossiblePossibly related (embedding) · 53%Artificial intelligence in oncology drug discovery: from target identification to therapeutic molecule generation - EurekAlert! →
- PossiblePossibly related (embedding) · 48%Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier - Pharmacy Times →
- PossiblePossibly related (embedding) · 60%AI in chemogenomics: Predicting drug-target interactions at scale - Drug Discovery News →
- PossiblePossibly related (embedding) · 54%Machine learning for drug metabolism prediction: CYPs, Phase II enzymes, and metabolite ID - Drug Discovery News →
- PossiblePossibly related (embedding) · 59%AI toxicity prediction: What machine learning models can (and can't) tell you about drug safety - Drug Discovery News →
- PossiblePossibly related (embedding) · 49%Machine Learning Predicts Survival in Breast Cancer Bone Metastasis - EMJ →
